AstraZeneca today announced the submission of a supplemental New Drug Application to the U.S. FDA for NEXIUM (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages 0 to 1 year old.
The details can be read here.
No comments:
Post a Comment